dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Meca-Lallana, Jose Eustasio |
dc.contributor.author | Oreja-Guevara, C. |
dc.contributor.author | Muñoz, D. |
dc.contributor.author | Olascoaga, J. |
dc.contributor.author | Pato, A. |
dc.contributor.author | Ramió-Torrentà, Lluís |
dc.contributor.author | Montalban Gairín, Xavier |
dc.date.accessioned | 2022-05-02T13:14:48Z |
dc.date.available | 2022-05-02T13:14:48Z |
dc.date.issued | 2021-10-13 |
dc.identifier.citation | Meca-Lallana JE, Oreja-Guevara C, Muñoz D, Olascoaga J, Pato A, Ramió-Torrentà L, et al. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. PLoS One. 2021 Oct 13;16(10):e0258437. |
dc.identifier.issn | 1932-6203 |
dc.identifier.uri | https://hdl.handle.net/11351/7453 |
dc.description | Esclerosi múltiple; Reaccions adverses; Infeccions respiratòries |
dc.description.sponsorship | The study was funded by the Academia Española de Esclerosis Múltiple y Otras Enfermedades Autoinmunes (ACADEM), with a restricted investigational grant form Novartis. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
dc.language.iso | eng |
dc.publisher | Public Library of Science |
dc.relation.ispartofseries | PLOS ONE;16(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Medicaments immunosupressors - Ús terapèutic - Efectes secundaris |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Immunosuppressive Agents |
dc.subject.mesh | Treatment Outcome |
dc.title | Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1371/journal.pone.0258437 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inmunosupresores |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1371/journal.pone.0258437 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Meca-Lallana JE] Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. [Oreja-Guevara C] Neurology Department, Hospital Clínico San Carlos, Madrid, Spain. [Muñoz D] Neurology Department, Hospital Xeral de Vigo, Vigo, Spain. [Olascoaga J] Neurology Department, Hospital Universitario Donostia, San Sebastián, Spain. [Pato A] Neurology Department, Hospital Povisa, Vigo, Spain. [Ramió-Torrentà L] Neurology Department, Hospital Universitari de Girona Dr. Josep Trueta, IDIBGI; Medical Sciences Department, University of Girona, Girona, Spain. [Montalbán X] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34644366 |
dc.identifier.wos | 000732519500044 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |